Stocksigma LogoStocksigma Logo

Molbio Diagnostics Reports Q2 and H1 FY27 Financial Results and Growth Outlook

Molbio Diagnostics reported Q2 FY27 revenue from operations of ₹259.0 Cr, EBITDA of ₹49.7 Cr (18.8% margin), and PAT of ₹7.7 Cr, impacted by 1–1.5 months

Molbio Diagnostics Reports Q2 and H1 FY27 Financial Results and Growth Outlook

Molbio Diagnostics Ltd · Investor Presentation · 05 Nov 2026, 11:07 pm

Molbio Diagnostics Reports Q2 and H1 FY27 Financial Results and Growth Outlook Molbio Diagnostics reported Q2 FY27 revenue from operations of ₹259.0 Cr, EBITDA of ₹49.7 Cr (18.8% margin), and PAT of ₹7.7 Cr, impacted by 1–1.5 months of rate-contract negotiations. For H1 FY27, revenue reached ₹667.4 Cr with EBITDA at ₹153.4 Cr (22.7% margin) and PAT of ₹60.4 Cr. Operating cash flow turned positive to ₹167.1 Cr. Management reiterated its 25% topline growth guidance for FY27, supported by non-linear revenue seasonality (H1 historically generating 35–45%), ongoing global expansion, and pipeline extensions into veterinary and digital pathology.

Original exchange filing (PDF)

More announcements from Molbio Diagnostics Ltd

All Molbio Diagnostics Ltd announcements